Argatroban for anticoagulation in continuous renal replacement therapy

Area of Science:

• Nephrology
• Critical Care Medicine
• Pharmacology

Background:

• Heparin-induced thrombocytopenia type II (HIT) complicates anticoagulation in critically ill patients requiring continuous renal replacement therapy (CRRT).
• Acute renal failure necessitates CRRT, increasing the risk of thrombotic events.
• Argatroban, a direct thrombin inhibitor, is an alternative anticoagulant in HIT patients.

Purpose of the Study:

• To evaluate argatroban for anticoagulation in CRRT for critically ill patients with HIT type II and acute renal failure.
• To identify predictors for optimal argatroban maintenance doses.
• To assess the efficacy and safety of argatroban anticoagulation during CRRT.

Main Methods:

• A prospective, dose-finding study was conducted in medical and surgical intensive care units.
• Thirty critically ill patients with HIT type II and acute renal failure requiring CRRT were included.
• Argatroban was used for anticoagulation during CRRT, with dose adjustments based on critical illness scores.

Main Results:

• Critical illness severity scores (APACHE-II, SAPS II) and indocyanine green plasma disappearance rate (ICG-PDR) correlated with argatroban maintenance doses.
• Formulas were derived to predict argatroban doses based on these scores, aiming for optimal anticoagulation.
• Argatroban demonstrated efficacy and safety, with a mean filter patency of 98% at 24 hours and only two minor bleeding episodes.

Conclusions:

• Critical illness scores (APACHE II, SAPS II) and ICG-PDR effectively predict the required argatroban maintenance dose for CRRT in HIT patients.
• These predictors help identify patients needing reduced argatroban doses, ensuring effective and safe anticoagulation.
• The study provides a dosing strategy for argatroban in CRRT, improving patient management in this complex population.